Haemonetics (NYSE:HAE) Upgraded at StockNews.com

StockNews.com upgraded shares of Haemonetics (NYSE:HAE) from a hold rating to a buy rating in a report issued on Friday morning.

A number of other analysts have also recently commented on HAE. Barrington Research reduced their price target on Haemonetics from $108.00 to $95.00 and set an “outperform” rating for the company in a research report on Friday. JMP Securities reduced their target price on shares of Haemonetics from $125.00 to $100.00 and set a “market outperform” rating for the company in a report on Friday. Bank of America cut shares of Haemonetics from a “neutral” rating to an “underperform” rating and decreased their target price for the stock from $95.00 to $68.00 in a research note on Friday. JPMorgan Chase & Co. started coverage on shares of Haemonetics in a research report on Friday, December 6th. They issued an “overweight” rating and a $116.00 price target for the company. Finally, Needham & Company LLC decreased their price objective on shares of Haemonetics from $112.00 to $108.00 and set a “buy” rating on the stock in a research report on Friday. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $101.67.

Haemonetics Stock Performance

HAE opened at $59.34 on Friday. The company’s 50 day moving average is $76.38 and its 200 day moving average is $78.32. The company has a current ratio of 3.97, a quick ratio of 2.09 and a debt-to-equity ratio of 1.35. The company has a market cap of $2.98 billion, a price-to-earnings ratio of 23.36, a PEG ratio of 0.98 and a beta of 0.39. Haemonetics has a 12-month low of $59.09 and a 12-month high of $97.97.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. On average, equities research analysts predict that Haemonetics will post 4.59 EPS for the current year.

Institutional Trading of Haemonetics

Several hedge funds have recently bought and sold shares of HAE. HighTower Advisors LLC increased its holdings in shares of Haemonetics by 7.8% in the fourth quarter. HighTower Advisors LLC now owns 3,353 shares of the medical instruments supplier’s stock worth $262,000 after purchasing an additional 244 shares during the last quarter. Wealthfront Advisers LLC purchased a new position in Haemonetics during the 4th quarter valued at approximately $7,849,000. Isthmus Partners LLC increased its stake in Haemonetics by 1.1% in the 4th quarter. Isthmus Partners LLC now owns 40,220 shares of the medical instruments supplier’s stock worth $3,140,000 after acquiring an additional 450 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Haemonetics by 10.7% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,460 shares of the medical instruments supplier’s stock worth $973,000 after acquiring an additional 1,202 shares in the last quarter. Finally, TradeLink Capital LLC bought a new position in shares of Haemonetics during the 4th quarter valued at approximately $902,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.